Details

Autor(en) / Beteiligte

• Jorizzo, Joseph, MD
• Dinehart, Scott, MD
• Matheson, Robert, MD
• Moore, Jeffrey K., MD
• Ling, Mark, MD, PhD
• Fox, Terry L., MS
• McRae, Scott, MS
• Fielder, Sandra, MD
• Lee, James H., MD, PhD

Titel

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head

Ist Teil von

• Journal of the American Academy of Dermatology, 2007-08, Vol.57 (2), p.265-268

Ort / Verlag

New York, NY: Mosby, Inc

Erscheinungsjahr

2007

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background A shorter dosing regimen of imiquimod for the treatment of actinic keratosis may be effective, with long-term clinical benefits. Objective Imiquimod in one or two shorter courses of treatment was evaluated. Methods Patients with actinic keratosis lesions on the head applied imiquimod or vehicle cream 3×/wk for 4 weeks (course 1). Patients with remaining lesions received another course of treatment. Complete and partial clearance rates were evaluated after course 1, after course 2 (overall), and 1 year later. Results Complete clearance rates were 26.8% (course 1) and 53.7% (overall). Partial clearance rates were 36.6% (course 1) and 61.0% (overall). One-year follow-up recurrence rates were 39% (imiquimod) and 57% (vehicle). Limitations Blinded investigators may have been biased toward patients treated with imiquimod identified by treatment site reactions. Conclusion Imiquimod 3×/wk in one or two courses of treatment appears to be effective for the treatment of actinic keratoses on the head, providing long-term clinical benefits. Some recurrences do occur, so long-term follow-up is recommended.